FitLife Brands, Inc. — Form 10-Q Summary
Business Context and Reporting Period
FitLife Brands, Inc. develops and sells nutritional supplements under NDS, PMD, SirenLabs, CoreActive, Metis Nutrition, iSatori, BioGenetic Laboratories, and Energize. NDS products are distributed principally through GNC, while iSatori products are sold through more than 25,000 specialty, mass-market, and online locations. The unaudited report covers the three and six months ended June 30, 2017, with comparisons to the same periods in 2016.
Financial Performance and Liquidity
| Metric | Three Months Ended June 30, 2017 | Three Months Ended June 30, 2016 | Six Months Ended June 30, 2017 | Six Months Ended June 30, 2016 |
|---|---|---|---|---|
| Revenue | $5.02 million | $8.66 million | $10.61 million | $16.27 million |
| Gross profit | $1.52 million | $3.81 million | $3.44 million | $7.16 million |
| Gross margin | 30.3% | 44.0% | 32.5% | 44.0% |
| Operating income (loss) | $(0.52) million | $1.22 million | $(0.82) million | $2.14 million |
| Net income (loss) | $(0.55) million | $1.08 million | $(0.88) million | $1.89 million |
| Basic EPS | $(0.05) | $0.10 | $(0.08) | $0.18 |
- Cash was $1.43 million at June 30, 2017, compared with $1.29 million at December 31, 2016.
- Current assets were $7.94 million and current liabilities were $5.33 million, implying current ratio of approximately 1.5x.
- Accounts receivable increased to $3.68 million from $2.79 million at year-end, while inventory declined to $2.56 million from $3.76 million.
- Total debt and advances were approximately $2.60 million, including a $1.95 million revolving credit line, $643,819 of term debt, and $7,004 of equipment-related notes.
- Cash provided by operating activities was $423,243 in the statement of cash flows, compared with $176,610 in the prior-year period. The MD&A reports this 2017 amount as $418,100; the filing does not explain the discrepancy.
- Investing activities used $10,033 and financing activities used $275,879 during the six months ended June 30, 2017. Cash increased by $137,331 to $1.43 million.
- Management reported net working capital of $2.66 million at June 30, 2017, versus $5.06 million at June 30, 2016.
Material Changes Versus the Prior Comparable Period
- Revenue declined 42.0% in the second quarter and 34.8% for the six-month period.
- NDS quarterly revenue decreased 40.0%, principally due to the absence of 2016 convention revenue and lower wholesale purchases by the largest distribution partner as it reduced inventory.
- iSatori quarterly revenue declined to $1.43 million from $2.67 million, primarily due to fewer new product introductions and restructuring at its largest third-party distributor.
- Gross margin contracted materially, partly because of approximately $376,000 of inventory write-offs in the second quarter, including approximately $276,000 related to picamilion.
- Six-month revenue included a one-time, non-recurring $700,000 margin-support credit memorandum with GNC.
- General and administrative expense declined 21.0% for the quarter and 21.0% for the six-month period, while selling and marketing expense declined 17.8% and 8.2%, respectively, reflecting cost reductions, integration savings, budget controls, and efficiencies.
- The company shifted from profit to loss: six-month net income of $1.89 million in 2016 became a net loss of $884,449 in 2017.
- Common shares outstanding increased to 10,504,472 from 10,483,389 at December 31, 2016. The company also issued 63,003 shares for director services valued at $35,000 and recognized $23,135 of option-related compensation expense.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management stated that existing cash and anticipated operating cash flow were expected to provide liquidity for the next 12 months, but this assessment is subject to significant financing risk.
- The $1.95 million U.S. Bank revolving credit line matured June 15, 2017 and was extended only through August 15, 2017. As of August 21, 2017, a condition of default existed. Management was negotiating an extension through December 15, 2017, but gave no assurance that it would be obtained. The line is secured by substantially all company assets.
- The company was not in compliance with certain financial covenants at June 30, 2017 and had requested a waiver or forbearance.
- Management expected sales impacts from the distributor restructuring and reduced inventory levels to stabilize in coming quarters and expected future new product introductions to support growth. No quantitative revenue or earnings guidance was provided.
- Goodwill of $4.42 million and indefinite-lived intangible assets of $1.88 million were recorded at quarter-end. Management did not identify an interim impairment trigger, but stated that the December 31, 2017 impairment test could result in a goodwill charge depending on forecasts and market conditions.
- GNC accounted for approximately 81.9% of gross sales before discounts and coupons during the six months ended June 30, 2017, and 84.7% of accounts receivable at June 30, 2017, creating substantial customer-concentration risk.
- The company disclosed an active lawsuit involving Testofen-related marketing claims. A separate HCG Activator lawsuit was dismissed June 27, 2017 without material financial impact.
- The company identified reliance on key customers and suppliers, competition, market demand, product performance, personnel retention, accounting changes, and distributor relationships as material risks. No new risk factors were added beyond those in the 2016 Form 10-K.
- Management concluded that disclosure controls and internal control over financial reporting were effective as of June 30, 2017; no material changes in controls were reported.
Important Facts for Investors to Verify
- Whether U.S. Bank extended or otherwise resolved the revolving credit line after the disclosed August 21, 2017 default condition, including any covenant waivers, collateral requirements, or repayment demands.
- The reconciliation of the $423,243 operating cash flow reported in the cash-flow statement and the $418,100 amount reported in MD&A.
- The sustainability of revenue after the $700,000 GNC credit memorandum, the 2017 convention comparison, and distributor inventory reductions.
- The potential for additional inventory write-offs, particularly involving picamilion, and the effect on gross margins.
- The results of the December 31, 2017 goodwill and indefinite-lived intangible asset impairment test.
- The financial exposure and status of the remaining Testofen-related litigation.
- The company’s ability to reduce its high dependence on GNC and maintain sufficient liquidity while carrying approximately $2.60 million of debt.